Pharma Logistics: Premium Pricing No Longer Justified by Specialization Alone

Pharma.Aero's secretary general Frank van Gelder has challenged a longstanding assumption in pharmaceutical logistics: that handling complex, high-value therapies automatically justifies premium pricing. His warning signals a fundamental shift in how shippers evaluate logistics partners and negotiate rates. Operators can no longer rely on the "pharma label" to command higher fees; instead, they must demonstrate concrete value through product integrity, treatment continuity, predictability, and measurable quality outcomes.

This structural change reflects broader industry maturation and competitive pressure. As pharmaceutical innovation accelerates, particularly in temperature-sensitive and time-critical treatments, logistics providers face a dual challenge: investing heavily in specialized infrastructure, personnel, and handling capabilities while simultaneously justifying those investments through demonstrable risk reduction and cost efficiency rather than markup alone. The distinction matters because pharma logistics costs are substantial and vary significantly by product category.

The underlying tension van Gelder identifies, the "healthcare pressure point," will reshape supplier selection criteria across the sector. Supply chain teams must now evaluate pharmaceutical logistics providers on specialization depth, measurable quality metrics, and total cost of ownership rather than rates alone. This shift favors operators with investment capacity, operational discipline, and transparency in service delivery.